🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

442 results for “Institut” Clear

  1. Pentasa Sachet 2 g depotgranulat, Pentasa PLACEBO Sachet 2g in the granule formulation specifically designed to resemble the active drug product

    The George Institute

    Lynch syndrome, which is increasing the risk of developing colorectal cancer

    phase 2 small molecule active

    1 trial

  2. Perjeta 420 mg concentrate for solution for infusion, Herceptin 150 mg powder for concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion

    The George Institute

    Newly diagnosed, non-metastatic early-stage triple-negative or HER2+ breast cancer

    phase 2 small molecule active

    1 trial

  3. Phase 1b/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3-DXd monotherapy and combinations in Patients with inoperable advanced breast cancer (ABC) after progression on T-DXd- (ICARUS BREAST 2)

    The George Institute

    Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-low defined as a score 1+ on immunohistochemistry [IHC] or as an IHC score 2+ and negative results on in situ hybridization (ISH) (cohort 2) ABC, and any hormone receptor (HR) status, who have progressed on trastuzumab deruxtecan (T-DXd). In addition to previous T-DXd, patients with HER2-pos tumors must have received prior treatment with trastuzumab (+/- pertuzumab) and taxanes and may have received T-DM1. Patients with HER2-low tumors must have received prior treatment with taxanes. Patients with HR-positive (HR+) and HER2-low tumor must have received prior treatment with endocrine therapy and CDK4/6 inhibitors.

    phase 2 other active

    1 trial

  4. Phase 2, Open label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in patients with advanced and/or unresectable Non-Small Cell Lung Cancer (NSCLC), with biomarker analysis to characterize response to therapy_ ICARUS LUNG 01

    The George Institute

    Adult patients with metastatic and/or unresectable Non-Small Cell Lung Cancer (NSCLC) who progressed on at least one line and not more than three lines of prior therapy for metastatic/unresectable NSCLC

    phase 2 other active

    1 trial

  5. Phase 2, Open label Study of Patritumab Deruxtecan (U3-1402), an Anti-HER3-Antibody Drug Conjugate (ADC), in patients with Advanced Breast Cancer, with biomarker analyses to characterize response to therapy

    The George Institute

    Patients with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-negative) advanced breast cancer (ABC) who have already received standard therapy for HR+/HER2-negative ABC, including only one line of chemotherapy for advanced/metastatic disease.

    phase 2 other active

    1 trial

  6. Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant Peritoneal Mesothelioma

    The George Institute

    Malignant Peritoneal Mesothelioma

    phase 2 other active

    1 trial

  7. Pimavanserina 34 mg placebo cápsulas, Pimavanserin tartrate

    The George Institute

    Major depressive disorder

    phase 2 small molecule active

    1 trial

  8. Placebo tablets are produced with the same appearance as the Valganciclovir tablets, with the same content except for the active compound., VALGANCICLOVIR

    The George Institute

    Glioblstoma WHO grade IV

    phase 2 small molecule active

    1 trial

  9. Plasma rich in growth factors

    The George Institute

    Low Reserve Ovarian

    phase 2 small molecule active

    1 trial

  10. Posaconazol STADA 100 mg magensaftresistente Tabletten, S65487 Solution for infusion 100 mg, Vidaza 25 mg/ml powder for suspension for injection

    The George Institute

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  11. Powder for concentrate for solution for infusion, Venclyxto 50 mg film-coated tablets, Zyloric 300 mg Tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion., Venclyxto 10 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Zyloric 100 mg Tablet

    The George Institute

    "Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)"

    phase 2 small molecule active

    1 trial

  12. Psilocybin (Usona Institute)

    United Therapeutics Europe Ltd

    Spinal Cord Injury

    phase 2 small molecule active

    1 trial

  13. Randomized phase 2 trial of two chemotherapy regimens plus or minus bevacizumab in patients with well differentiated pancreatic neuroendocrine tumors

    The George Institute

    Pancreatic well differentiated neuroendocrine tumors (NET)

    phase 2 other active

    1 trial

  14. Retifanlimab (INCMGA00012), HOLOXAN 2000 mg, poudre pour usage parentéral, DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion

    The George Institute

    Adult patients with treatment-naïve surgically non-metastatic and resectable primary retroperitoneal, limbs and trunk wall undifferentiated pleomorphic sarcomas.

    phase 2 small molecule active

    1 trial

  15. Rifampicin 150 mg Capsules, RIMSTAR®, COMPRIMIDOS RECUBIERTOS CON PELÍCULA, Rifampicin 300 mg Capsules

    The George Institute

    TUBERCULOSIS

    phase 2 small molecule active

    1 trial

  16. Rimactan 300 mg hörð hylki., Moxifloxacin Tillomed 400 mg film coated tablets, LINEZOLID, RIMSTAR®, COMPRIMIDOS RECUBIERTOS CON PELÍCULA, Hidroxil B1-B6-B12 comprimidos recubiertos con película, Zyvoxid 600 mg Filmtabletten

    The George Institute

    Bacilliferous pulmonary tuberculosis

    phase 2 small molecule active

    1 trial

  17. S095029/Sym025, LIBTAYO 350 mg concentrate for solution for infusion., S095018/Sym023, S095024/Sym024

    The George Institute

    Non-small cell lung cancer (NSCLC): - Locally advanced NSCLC where participants are not candidates for surgical resection and/or definitive chemoradiation, or - Metastatic NSCLC

    phase 2 small molecule active

    1 trial

  18. S230815 Solution for injection 10mg/ml

    The George Institute

    KCNT1-related Developmental and Epileptic Encephalopathy

    phase 2 small molecule active

    1 trial

  19. S95012 concentrate solution for infusion 400mg/ 16 ml, Gazyvaro 1,000 mg concentrate for solution for infusion.

    The George Institute

    Soild Tumors

    phase 2 small molecule active

    1 trial

  20. SAKK 66/22: Intratumoral INT230-6 followed by neoadjuvant immuno-chemotherapy in patients with early triple-negative breast cancer (TNBC). An open-label randomized two-cohort phase 2 clinical trial. INVINCIBLE-4-SAKK

    The George Institute

    Early triple-negative breast cancer (TNBC)

    phase 2 other active

    1 trial

  21. SARCLISA 20mg/mL concentrate for solution for infusion., CellProtect

    The George Institute

    Multiple myeloma

    phase 2 small molecule active

    1 trial

  22. SODIUM CHLORIDE, LIDOCAINE HYDROCHLORIDE MONOHYDRATE

    The George Institute

    Colon cancer

    phase 2 small molecule active

    1 trial

  23. SPM 962

    Otsuka Beijing Research Institute

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  24. SYNTOCINON 40 i.e./ml pršilo za nos, raztopina, Oxytocin Placebo

    The George Institute

    schizophrenia or other primary psychotic disorders (SSD)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources